Stryker ROA 2006-2018 | SYK
Current and historical return on assets (ROA) values for Stryker (SYK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Stryker ROA for the three months ending September 30, 2018 was 12.26%.
| Stryker ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-09-30 | $1.24B | $22.08B | 5.62% |
| 2018-06-30 | $1.08B | $21.57B | 4.94% |
| 2018-03-31 | $1.02B | $22.13B | 4.68% |
| 2017-12-31 | $1.02B | $22.20B | 4.77% |
| 2017-09-30 | $1.78B | $21.49B | 8.50% |
| 2017-06-30 | $1.70B | $21.29B | 8.25% |
| 2017-03-31 | $1.69B | $20.52B | 8.27% |
| 2016-12-31 | $1.65B | $20.44B | 8.15% |
| 2016-09-30 | $1.66B | $20.19B | 8.66% |
| 2016-06-30 | $1.61B | $20.52B | 8.88% |
| 2016-03-31 | $1.62B | $19.67B | 9.42% |
| 2015-12-31 | $1.44B | $16.22B | 8.78% |
| 2015-09-30 | $1.18B | $15.92B | 7.07% |
| 2015-06-30 | $0.93B | $16.82B | 5.47% |
| 2015-03-31 | $0.67B | $16.58B | 3.90% |
| 2014-12-31 | $0.52B | $17.28B | 3.02% |
| 2014-09-30 | $0.64B | $17.52B | 3.85% |
| 2014-06-30 | $0.69B | $17.23B | 4.29% |
| 2014-03-31 | $0.77B | $16.16B | 5.05% |
| 2013-12-31 | $1.01B | $15.74B | 6.81% |
| 2013-09-30 | $0.89B | $14.88B | 6.29% |
| 2013-06-30 | $1.14B | $14.38B | 8.37% |
| 2013-03-31 | $1.25B | $14.09B | 9.57% |
| 2012-12-31 | $1.30B | $13.21B | 10.24% |
| 2012-09-30 | $1.43B | $12.78B | 11.51% |
| 2012-06-30 | $1.40B | $12.26B | 11.46% |
| 2012-03-31 | $1.39B | $12.46B | 11.50% |
| 2011-12-31 | $1.35B | $12.15B | 11.43% |
| 2011-09-30 | $1.24B | $12.08B | 10.82% |
| 2011-06-30 | $1.25B | $11.60B | 11.23% |
| 2011-03-31 | $1.26B | $11.23B | 11.71% |
| 2010-12-31 | $1.27B | $10.90B | 12.17% |
| 2010-09-30 | $1.28B | $10.77B | 12.84% |
| 2010-06-30 | $1.18B | $10.06B | 12.48% |
| 2010-03-31 | $1.15B | $10.10B | 12.92% |
| 2009-12-31 | $1.11B | $9.07B | 13.40% |
| 2009-09-30 | $1.08B | $8.46B | 13.67% |
| 2009-06-30 | $1.12B | $7.92B | 14.65% |
| 2009-03-31 | $1.14B | $7.59B | 14.80% |
| 2008-12-31 | $1.15B | $7.60B | 14.85% |
| 2008-09-30 | $1.15B | $7.58B | 14.94% |
| 2008-06-30 | $1.10B | $8.03B | 14.70% |
| 2008-03-31 | $1.07B | $7.75B | 15.01% |
| 2007-12-31 | $1.02B | $7.35B | 15.25% |
| 2007-09-30 | $0.97B | $6.86B | 15.38% |
| 2007-06-30 | $0.93B | $6.42B | 15.63% |
| 2007-03-31 | $0.87B | $6.08B | 15.57% |
| 2006-12-31 | $0.78B | $5.87B | 14.56% |
| 2006-09-30 | $0.73B | $5.40B | 14.21% |
| 2006-06-30 | $0.66B | $5.11B | 13.56% |
| 2006-03-31 | $0.63B | $4.99B | 13.48% |
| 2005-12-31 | $0.64B | $4.99B | 14.61% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $62.796B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $124.342B | 19.06 |
| Abbott Laboratories (ABT) | United States | $122.048B | 24.73 |
| Boston Scientific (BSX) | United States | $50.730B | 25.64 |
| Baxter (BAX) | United States | $33.541B | 21.66 |
| Zimmer Biomet Holdings (ZBH) | United States | $23.031B | 14.94 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.007B | 0.00 |
| ResMed (RMD) | United States | $14.492B | 27.64 |
| Canopy Growth (CGC) | Canada | $8.934B | 0.00 |
| Perrigo (PRGO) | Ireland | $8.884B | 13.48 |
| Bio-Rad Laboratories (BIO) | United States | $8.054B | 51.50 |
| Aurora Cannabis (ACB) | Canada | $6.462B | 35.26 |
| Hill-Rom Holdings (HRC) | United States | $6.201B | 19.66 |
| Haemonetics (HAE) | United States | $5.495B | 48.33 |
| Insulet (PODD) | United States | $4.770B | 0.00 |
| ICU Medical (ICUI) | United States | $4.529B | 25.23 |
| Hutchison China MediTech (HCM) | China | $4.274B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.987B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.869B | 0.00 |
| Neogen (NEOG) | United States | $3.219B | 48.74 |
| National Vision Holdings (EYE) | United States | $3.101B | 61.33 |
| NuVasive (NUVA) | United States | $2.972B | 27.65 |
| Aphria (APHA) | $2.572B | 0.00 | |
| Quidel (QDEL) | United States | $2.478B | 32.30 |
| NxStage Medical (NXTM) | United States | $1.924B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.476B | 20.89 |
| AtriCure (ATRC) | United States | $1.174B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.015B | 1462.50 |
| VAREX IMAGING (VREX) | United States | $0.992B | 19.93 |
| Meridian Bioscience (VIVO) | United States | $0.827B | 26.35 |
| PetIQ (PETQ) | United States | $0.803B | 22.83 |
| OraSure Technologies (OSUR) | United States | $0.793B | 44.65 |
| Surmodics (SRDX) | United States | $0.776B | 118.55 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.755B | 24.22 |
| Cerus (CERS) | United States | $0.719B | 0.00 |
| MacroGenics (MGNX) | United States | $0.710B | 0.00 |
| Omeros (OMER) | United States | $0.623B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.590B | 18.27 |
| Owens & Minor (OMI) | United States | $0.558B | 6.31 |
| Insys Therapeutics (INSY) | United States | $0.542B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.518B | 25.45 |
| NanoString Technologies (NSTG) | United States | $0.481B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.438B | 0.00 |
| Evolus (EOLS) | United States | $0.399B | 0.00 |
| Quanterix (QTRX) | United States | $0.359B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.327B | 21.12 |
| Cytosorbents (CTSO) | United States | $0.302B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.255B | 0.00 |
| Surface Oncology (SURF) | United States | $0.226B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.211B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.206B | 278.75 |
| Bovie Medical (BVX) | United States | $0.201B | 0.00 |
| Chimerix (CMRX) | United States | $0.161B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.148B | 0.00 |
| Fonar (FONR) | United States | $0.139B | 6.96 |
| Chembio Diagnostics (CEMI) | United States | $0.104B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.081B | 0.00 |
| United-Guardian (UG) | United States | $0.079B | 16.63 |
| Female Health (VERU) | United States | $0.079B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.077B | 24.40 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.070B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.067B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.056B | 0.00 |
| Neurotrope (NTRP) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.028B | 0.00 |
| Myomo (MYO) | United States | $0.025B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.021B | 0.00 |
| Senestech (SNES) | United States | $0.019B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.019B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.000B | 0.00 |
